Two Cigarettes: Nicotine, Hemp and the White Matter They Both Reach

keywords: nicotine hemp cannabinoids myelin oligodendrocyte white matter

Two plants. Rolled in paper, sold at the same counter for most of the twentieth century. One carries nicotine, the other carries cannabinoids. Both have been celebrated and condemned with equal force, often by the same people in the same decade. Both are now the subject of serious medical research. And both, when you follow the biology past the politics, arrive at the same address: the white matter of the brain, and the oligodendrocyte precursor cells that are building it.

That is not a coincidence. It is a key.

This article is a companion to the nicotine article on this site. Nothing here constitutes medical advice. I hold a PhD, not a medical degree.

Two receptor systems, both native to white matter

The nicotine article established that the nicotinic acetylcholine receptor is expressed on oligodendrocyte precursor cells, and that nicotine, arriving from outside, borrows a receptor the nervous system designed for its own signalling. That is already a striking finding.

The hemp story goes one step further.

The cannabis plant contains two primary active compounds: THC, which is psychoactive, and CBD, which is not. Both act on the endocannabinoid system, a network of receptors distributed throughout the brain and body that the nervous system uses for its own internal signalling. These receptors, designated CB1 and CB2, are expressed not only on neurons but on oligodendrocyte precursor cells. And here is the detail that changes the picture: OPCs do not merely receive cannabinoid signals. They produce their own endocannabinoids. The OPC is not just listening to an external signal through a borrowed receptor. It is part of the conversation. The cell that builds myelin synthesises cannabinoid-like molecules as part of its own developmental process.

With nicotine, the nervous system’s own ligand is acetylcholine, a neurotransmitter. With cannabinoids, the nervous system’s own ligands are molecules the OPCs make themselves. The hemp plant has found its way into a signalling system that OPCs use to manage their own maturation.

What each plant does to the myelination process

The two molecules affect myelination in overlapping but distinct ways.

Nicotine, acting through the nicotinic receptor on OPCs, promotes the calcium signal that drives differentiation. It supports the transition from precursor to mature myelinating cell. In conditions where that transition is blocked, as in multiple sclerosis, nicotine in animal models reduces the inflammatory environment and encourages the remyelination response.

Cannabinoids, acting through CB1 and CB2 receptors on OPCs, promote OPC survival, proliferation, migration, and differentiation. CBD specifically protects OPCs against the kinds of cell death that inflammation triggers. THC, in acute low doses in developing animals, has been shown to enhance OPC maturation and increase myelination in the subcortical white matter. In multiple sclerosis animal models, cannabinoids consistently reduce demyelination, suppress the autoimmune attack on white matter, and promote remyelination. The clinical evidence has not kept pace with the animal evidence, but Sativex, a 1:1 combination of THC and CBD, has been licensed in the United Kingdom since 2010 for the treatment of MS spasticity, and is the only plant-derived cannabinoid product with regulatory approval for a neurological condition.

Nicotine’s clinical trial in Parkinson’s disease failed to show benefit after one year of transdermal treatment. Cannabinoids have reached a licensed product in MS. On that measure, hemp is currently further ahead.

The same reversal

Both plants carry the same structural paradox that the nicotine article described. When the signal lands in a healthy cell involved in development or repair, it supports the myelination process. When the timing is wrong, the dose is wrong, or the cell receiving the signal is not supposed to be proliferating, the same signal can do harm.

Prenatal THC exposure, following the same logic as prenatal nicotine exposure, disrupts the normal sequence of myelination. The endocannabinoid system is active very early in fetal development, and OPCs are present in the developing brain long before birth. Activating those receptors at the wrong developmental moment, with exogenous cannabinoids arriving from outside in concentrations and timings the developing system was not designed to handle, produces aberrant myelination rather than enhanced myelination. A 2025 study in zebrafish confirmed that pharmacological activation of the endocannabinoid system during development leads to oligodendrocytes wrapping the wrong targets.

The molecule is not the medicine. The timing is part of the medicine. And the developing brain is not the right address.

What the Myelin Mind makes of this

There is something philosophically interesting in the fact that both of these plants have found their way to the same white matter address through different routes, and that the body was already using versions of both signals for its own purposes.

The nervous system generates acetylcholine along firing axons, using it in part to tell OPCs that activity is happening and that myelination is needed. The nervous system also generates endocannabinoids within OPCs themselves, using them as part of the internal coordination of the myelination process. Both signals are endogenous. Both receptor systems are present on the cells that build white matter. And both plants have, through millennia of human use, arrived at those same receptors through entirely separate molecular routes.

The Myelin Mind thesis argues that consciousness arises at the encounter between incoming signal and accumulated myelinated condition: between the world arriving and the white matter that meets it. What the two-cigarettes story suggests is that the myelination process is not a passive background condition. It is an actively managed, chemically sensitive, environmentally responsive process with its own native signalling vocabulary, and that some of what plants have evolved to produce finds its way into that vocabulary because the receptor was already there.

Whether nicotine or cannabinoids will eventually contribute to the treatment of demyelinating disease in a clinically validated way remains open. The animal evidence for both is more consistent than the clinical evidence for either. What is already clear is that both plants are speaking to white matter, and that white matter was already fluent in both languages.

Two Cigarettes: Nicotine, Hemp and the White Matter They Both Reach

Two receptor systems, both native to white matter

What each plant does to the myelination process

The same reversal

What the Myelin Mind makes of this

Further Reading

Leave a Reply Cancel reply